Büller HR - Search Results

1

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.

Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators. Raskob GE, et al. Among authors: buller hr. N Engl J Med. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12. N Engl J Med. 2018. PMID: 29231094 Free article. Clinical Trial.

2

The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders.

Meinardi JR, Middeldorp S, de Kam PJ, Koopman MM, van Pampus EC, Hamulyák K, Prins MH, Büller HR, van der Meer J. Meinardi JR, et al. Among authors: buller hr. Br J Haematol. 2002 Mar;116(3):625-31. doi: 10.1046/j.0007-1048.2001.03303.x. Br J Haematol. 2002. PMID: 11849222 Free article.

3

Direct thrombin inhibitors in acute coronary syndromes: present and future.

Weitz JI, Buller HR. Weitz JI, et al. Among authors: buller hr. Circulation. 2002 Feb 26;105(8):1004-11. doi: 10.1161/hc0802.104331. Circulation. 2002. PMID: 11864933 Review. No abstract available.

4

Treatment of symptomatic venous thromboembolism: improving outcomes.

Büller HR. Büller HR. Semin Thromb Hemost. 2002 Jun;28 Suppl 2:41-8. doi: 10.1055/s-2002-32315. Semin Thromb Hemost. 2002. PMID: 12073179 Review.

5

Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?

Strebel N, Prins M, Agnelli G, Büller HR. Strebel N, et al. Among authors: buller hr. Arch Intern Med. 2002 Jul 8;162(13):1451-6. doi: 10.1001/archinte.162.13.1451. Arch Intern Med. 2002. PMID: 12090880 Review.

6

Travel and the risk of symptomatic venous thromboembolism.

ten Wolde M, Kraaijenhagen RA, Schiereck J, Hagen PJ, Mathijssen JJ, Mac Gillavry MR, Koopman MM, Büller HR. ten Wolde M, et al. Among authors: buller hr. Thromb Haemost. 2003 Mar;89(3):499-505. Thromb Haemost. 2003. PMID: 12624634

7

Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.

Harenberg J, Riess H, Büller HR, Brom J, Weidinger G, Huisman MV. Harenberg J, et al. Among authors: buller hr. Haematologica. 2003 Oct;88(10):1157-62. Haematologica. 2003. PMID: 14555312 Clinical Trial.

8

Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice.

Bank I, Scavenius MP, Büller HR, Middeldorp S. Bank I, et al. Among authors: buller hr. Thromb Res. 2004;113(1):7-12. doi: 10.1016/j.thromres.2004.02.002. Thromb Res. 2004. PMID: 15081560 Clinical Trial.

9

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.

Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW; Matisse Investigators. Büller HR, et al. Ann Intern Med. 2004 Jun 1;140(11):867-73. doi: 10.7326/0003-4819-140-11-200406010-00007. Ann Intern Med. 2004. PMID: 15172900 Clinical Trial.

10

Antithrombotic therapy and cancer.

Di Nisio M, Squizzato A, Klerk CP, Richel DJ, Büller HR. Di Nisio M, et al. Among authors: buller hr. Curr Opin Hematol. 2004 May;11(3):187-91. doi: 10.1097/01.moh.0000130317.18163.83. Curr Opin Hematol. 2004. PMID: 15257019 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

733 results

Search Page